Literature DB >> 29149705

Toll-like receptor 4 deficiency increases resistance in sepsis-induced immune dysfunction.

Chao Cao1, Yanfen Chai1, Songtao Shou1, Jun Wang1, Ying Huang1, Tao Ma2.   

Abstract

Sepsis constitutes a serious life-threatening syndrome associated with complications of deregulated inflammatory response against endotoxin/lipopolysaccharide (LPS)-mediated severe infection. Toll-like receptor 4 (TLR4) plays a critical role in the activation of innate immunity through recognition of LPS. However, the impact of TLR4 signaling on the development of sepsis-induced immune dysfunction remains unclear. The aim of this study was to investigate the effect of TLR4 on regulatory T cells (Tregs) and its potential mechanism. To simulate sepsis, male C57BL/6 (wild-type) and C57BL/10ScNJNJU (TLR4-/-) mice were subjected to cecal ligation and puncture (CLP). After 24h, pro- and anti-inflammatory cytokine secretion, neutrophil and macrophage lung and liver infiltration were assessed to evaluate the sepsis-induced inflammatory response. The quantity and apoptotic rate of Tregs were measured. The expression of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and forkhead/winged helix transcription factor p3 (Foxp3) were analyzed. Cytokine (i.e., TNF-α, IL-2, IL-10, and IL-4) secretion by Tregs in the cell suspensions and the suppressive activity on CD4+CD25- T cell proliferation were also determined in vitro. At 24h after the CLP procedure, the wild-type mice exhibited increased Treg levels and expression, and secreted inflammatory factors in the serum were markedly overproduced. However, the TLR4-/- mice attenuated the increased Treg expression and inflammatory factor overproduction. These results indicate that in a model of post-septic mice, TLR4 deficiency improves immune paralysis by attenuating Treg activity and restoring a pro-inflammatory cytokine balance. Thus, modulation of the TLR4 activity may be useful in preventing immune dysfunction in sepsis.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Immune dysfunction; Inflammatory mediator; Regulatory T cell; Sepsis; Toll-like receptor 4

Mesh:

Substances:

Year:  2017        PMID: 29149705     DOI: 10.1016/j.intimp.2017.11.006

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  14 in total

1.  Loss of tissue-nonspecific alkaline phosphatase (TNAP) enzyme activity in cerebral microvessels is coupled to persistent neuroinflammation and behavioral deficits in late sepsis.

Authors:  Divine C Nwafor; Sreeparna Chakraborty; Allison L Brichacek; Sujung Jun; Catheryne A Gambill; Wei Wang; Elizabeth B Engler-Chiurazzi; Duaa Dakhlallah; Anthony B Pinkerton; José Luis Millán; Stanley A Benkovic; Candice M Brown
Journal:  Brain Behav Immun       Date:  2019-11-25       Impact factor: 7.217

2.  Effects of the interaction of Notch and TLR4 pathways on inflammation and heart function in septic heart.

Authors:  Ziyang Liu; Wenli Li; Yang Cao; Xiaoxia Zhang; Kai Yang; Fukang Yin; Meng Yang; Peng Peng
Journal:  Open Life Sci       Date:  2022-07-13       Impact factor: 1.311

3.  TLR4-SIRT3 Mechanism Modulates Mitochondrial and Redox Homeostasis and Promotes EPCs Recruitment and Survival.

Authors:  Xiaotian Wang; Weidong Yao; Meihui Wang; Junhui Zhu; Liang Xia
Journal:  Oxid Med Cell Longev       Date:  2022-07-04       Impact factor: 7.310

4.  BCG vaccination-induced emergency granulopoiesis provides rapid protection from neonatal sepsis.

Authors:  Byron Brook; Danny J Harbeson; Casey P Shannon; Bing Cai; Daniel He; Rym Ben-Othman; Freddy Francis; Joe Huang; Natallia Varankovich; Aaron Liu; Winnie Bao; Morten Bjerregaard-Andersen; Frederik Schaltz-Buchholzer; Lilica Sanca; Christian N Golding; Kristina Lindberg Larsen; Ofer Levy; Beate Kampmann; Rusung Tan; Adrian Charles; James L Wynn; Frank Shann; Peter Aaby; Christine S Benn; Scott J Tebbutt; Tobias R Kollmann; Nelly Amenyogbe
Journal:  Sci Transl Med       Date:  2020-05-06       Impact factor: 17.956

5.  The Potential of Phage Therapy in Sepsis.

Authors:  Andrzej Górski; Ewa Jończyk-Matysiak; Marzanna Łusiak-Szelachowska; Ryszard Międzybrodzki; Beata Weber-Dąbrowska; Jan Borysowski
Journal:  Front Immunol       Date:  2017-12-11       Impact factor: 7.561

6.  Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse Sepsis.

Authors:  Andreas von Knethen; Anne Schäfer; Laura Kuchler; Tilo Knape; Urs Christen; Edith Hintermann; Beate Fißlthaler; Katrin Schröder; Ralf P Brandes; Berit Genz; Kerstin Abshagen; Brigitte M Pützer; Lisa K Sha; Andreas Weigert; Shahzad N Syed; Martin Schulz; Ajay M Shah; Andreas Ernst; Mateusz Putyrski; Fabian Finkelmeier; Marina Pesic; Florian Greten; Michael Hogardt; Volkhard A J Kempf; Sandra Gunne; Michael J Parnham; Bernhard Brüne
Journal:  Theranostics       Date:  2019-03-16       Impact factor: 11.556

Review 7.  Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis.

Authors:  Chao Cao; Muming Yu; Yanfen Chai
Journal:  Cell Death Dis       Date:  2019-10-14       Impact factor: 8.469

8.  Identification of key miRNA‑mRNA pairs in septic mice by bioinformatics analysis.

Authors:  Jianxin Chen; Min Lin; Sen Zhang
Journal:  Mol Med Rep       Date:  2019-08-20       Impact factor: 2.952

9.  Atezolizumab alleviates the immunosuppression induced by PD‑L1‑positive neutrophils and improves the survival of mice during sepsis.

Authors:  Jianxin Chen; Ruiyuan Chen; Shaoxiong Huang; Bin Zu; Sen Zhang
Journal:  Mol Med Rep       Date:  2020-12-15       Impact factor: 2.952

10.  NEAT1 Promotes LPS-induced Inflammatory Injury in Macrophages by Regulating MiR-17-5p/TLR4.

Authors:  Yanhui Li; Wei Guo; Yeping Cai
Journal:  Open Med (Wars)       Date:  2020-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.